However, unlike in other lymphomas, such as Hodgkin lymphoma, in which the blockade of these immune checkpoint molecules is an effective therapeutic approach, and despite the expression of PD-1 and PD-L1 in a significant proportion of DLBCLs, checkpoint blockade therapy has so far shown limited efficacy in this disease (29–31). Here, CD274 is linked to lymphoma.